Biolinerx Ltd ADR (BLRX)

$2.88 0.00 (N/A)
Market Cap 12.53M
Revenue (ttm) 28.94M
Net Income (ttm) -9.22M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -31.86%
Debt to Equity Ratio 0.52
Volume 48,800
Avg Vol 25,014
Day's Range N/A - N/A
Shares Out 4.35M
Stochastic %K 47%
Beta 1.28
Analysts Strong Sell
Price Target $20.33

Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 8 642 9100
Fax: 972 8 642 9101
Address:
Modi’in Technology Park, 2 HaMa’ayan Street, Hevel Modi'in, Israel
gargoyl
gargoyl Jan. 19 at 5:09 AM
$BLRX 🤔 …. 🦍
0 · Reply
gargoyl
gargoyl Jan. 19 at 5:09 AM
$BLRX 👀
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Jan. 16 at 8:04 PM
$BLRX Cycle Trading Signal 🔥 app 🔥
0 · Reply
gargoyl
gargoyl Jan. 16 at 5:41 PM
$BLRX it’s freedom of choice of trade , I make no excuses, exceptions or apologies, it’s a button of buy or sell , but the rub is in patience, once the decision is made and the DD theses holds they “bank “ on you changing your feelings, this is not about feelings, watch this one , it’s real . 🦍
0 · Reply
gargoyl
gargoyl Jan. 16 at 3:26 PM
$BLRX MM counters a 10k Bid with a 20k Ask , spread book wide open , watch as he reconciles the offset , brings her back over $3 .. the forced illusion of weakness accentuates the move up on balance .. Manipulation is temporary, treating cancer is indelible
0 · Reply
gargoyl
gargoyl Jan. 16 at 2:29 PM
$BLRX look 🏃‍♀️
0 · Reply
mfish11
mfish11 Jan. 15 at 8:34 PM
$BLRX this gonna make me rich one day
1 · Reply
gargoyl
gargoyl Jan. 15 at 2:24 PM
$BLRX 👀 - spoofing at 3.10 - past month channel consolidation between 2.80 and 3.10 - RSI primed break 60 - $XBI run 🏃‍♂️ - nearing next ER - MM playing the pull back game widening her book - my book All point to we break $3.00 today 💪 strong Target 🎯 $12 -$18 $REGN long the 🦋
0 · Reply
gargoyl
gargoyl Jan. 14 at 2:45 PM
$VSTM $BLRX 🔮 One will be down 10% Other up 10% today
0 · Reply
silentmaxx
silentmaxx Jan. 13 at 4:13 PM
$BLRX
0 · Reply
Latest News on BLRX
BioLineRx Ltd. (BLRX) Q3 2025 Earnings Call Transcript

Nov 24, 2025, 10:53 AM EST - 2 months ago

BioLineRx Ltd. (BLRX) Q3 2025 Earnings Call Transcript

BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 24, 2025, 7:00 AM EST - 2 months ago

BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

Nov 18, 2025, 7:00 AM EST - 2 months ago

BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types

Nov 17, 2025, 7:00 AM EST - 2 months ago

BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types

BioLineRx Ltd. - Special Call

Sep 29, 2025, 3:27 PM EDT - 4 months ago

BioLineRx Ltd. - Special Call

BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers

Sep 29, 2025, 7:00 AM EDT - 4 months ago

BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers

BioLineRx Ltd. (BLRX) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 10:44 AM EDT - 5 months ago

BioLineRx Ltd. (BLRX) Q2 2025 Earnings Call Transcript

BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 7:00 AM EDT - 5 months ago

BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update

BioLineRx to Report Second Quarter 2025 Results on August 14, 2025

Aug 7, 2025, 7:00 AM EDT - 5 months ago

BioLineRx to Report Second Quarter 2025 Results on August 14, 2025

Why Is Nano-Cap BioLineRx Stock Surging On Friday?

May 30, 2025, 1:58 PM EDT - 8 months ago

Why Is Nano-Cap BioLineRx Stock Surging On Friday?

BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting

May 30, 2025, 7:00 AM EDT - 8 months ago

BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting

BioLineRx Ltd. (BLRX) Q1 2025 Earnings Call Transcript

May 27, 2025, 12:55 PM EDT - 8 months ago

BioLineRx Ltd. (BLRX) Q1 2025 Earnings Call Transcript

BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 27, 2025, 7:00 AM EDT - 8 months ago

BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update

BioLineRx to Report First Quarter 2025 Results on May 27, 2025

May 20, 2025, 7:00 AM EDT - 8 months ago

BioLineRx to Report First Quarter 2025 Results on May 27, 2025

BioLineRx Ltd. (BLRX) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 10:52 AM EDT - 10 months ago

BioLineRx Ltd. (BLRX) Q4 2024 Earnings Call Transcript

BioLineRx Reports 2024 Financial Results and Provides Corporate Update

Mar 31, 2025, 7:00 AM EDT - 10 months ago

BioLineRx Reports 2024 Financial Results and Provides Corporate Update

BioLineRx to Report 2024 Annual Results on March 31, 2025

Mar 24, 2025, 7:00 AM EDT - 10 months ago

BioLineRx to Report 2024 Annual Results on March 31, 2025

BioLineRx Issues Letter to Shareholders

Jan 21, 2025, 7:00 AM EST - 1 year ago

BioLineRx Issues Letter to Shareholders

BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares

Jan 17, 2025, 7:00 AM EST - 1 year ago

BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares

Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet

Jan 6, 2025, 2:01 PM EST - 1 year ago

Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet

BioLineRx Announces $10 Million Registered Direct Offering

Jan 6, 2025, 8:57 AM EST - 1 year ago

BioLineRx Announces $10 Million Registered Direct Offering

BioLineRx Ltd. (BLRX) Q3 2024 Earnings Call Transcript

Nov 25, 2024, 10:58 AM EST - 1 year ago

BioLineRx Ltd. (BLRX) Q3 2024 Earnings Call Transcript

BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value

Nov 25, 2024, 7:00 AM EST - 1 year ago

BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

Nov 21, 2024, 6:30 AM EST - 1 year ago

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

Nov 20, 2024, 7:19 AM EST - 1 year ago

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024

Nov 5, 2024, 9:00 AM EST - 1 year ago

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024

BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide

Oct 16, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide

BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection

Sep 17, 2024, 1:01 PM EDT - 1 year ago

BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection

BioLineRx Ltd. (BLRX) Q2 2024 Earnings Call Transcript

Aug 15, 2024, 3:03 PM EDT - 1 year ago

BioLineRx Ltd. (BLRX) Q2 2024 Earnings Call Transcript

BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

Aug 15, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx to Report Second Quarter 2024 Results on August 15, 2024

Aug 8, 2024, 7:00 AM EDT - 1 year ago

BioLineRx to Report Second Quarter 2024 Results on August 15, 2024

BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)

May 30, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)

BioLineRx Ltd. (BLRX) Q1 2024 Earnings Call Transcript

May 28, 2024, 5:56 PM EDT - 1 year ago

BioLineRx Ltd. (BLRX) Q1 2024 Earnings Call Transcript

BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

May 28, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

May 24, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

BioLineRx to Report First Quarter 2024 Results on May 28, 2024

May 22, 2024, 7:00 AM EDT - 1 year ago

BioLineRx to Report First Quarter 2024 Results on May 28, 2024

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

May 17, 2024, 5:00 PM EDT - 1 year ago

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024

May 6, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024

BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting

Apr 17, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting

BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement

Apr 10, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement

BioLineRx Announces $6 Million Registered Direct Offering

Apr 1, 2024, 9:00 AM EDT - 1 year ago

BioLineRx Announces $6 Million Registered Direct Offering

BioLineRx Ltd. (BLRX) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 11:38 AM EDT - 1 year ago

BioLineRx Ltd. (BLRX) Q4 2023 Earnings Call Transcript

BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates

Mar 26, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx to Report 2023 Annual Financial Results on March 26, 2024

Mar 20, 2024, 7:00 AM EDT - 1 year ago

BioLineRx to Report 2023 Annual Financial Results on March 26, 2024

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

Mar 6, 2024, 8:00 AM EST - 2 years ago

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

CADL IMRX ONCY

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production

Mar 4, 2024, 7:00 AM EST - 2 years ago

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production

BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)

Feb 28, 2024, 7:00 AM EST - 2 years ago

BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)

BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Feb 16, 2024, 7:00 AM EST - 2 years ago

BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

Dec 21, 2023, 7:00 AM EST - 2 years ago

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

BioLineRx: Still A Buy, With Some Questions

Dec 4, 2023, 6:42 PM EST - 2 years ago

BioLineRx: Still A Buy, With Some Questions

gargoyl
gargoyl Jan. 19 at 5:09 AM
$BLRX 🤔 …. 🦍
0 · Reply
gargoyl
gargoyl Jan. 19 at 5:09 AM
$BLRX 👀
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Jan. 16 at 8:04 PM
$BLRX Cycle Trading Signal 🔥 app 🔥
0 · Reply
gargoyl
gargoyl Jan. 16 at 5:41 PM
$BLRX it’s freedom of choice of trade , I make no excuses, exceptions or apologies, it’s a button of buy or sell , but the rub is in patience, once the decision is made and the DD theses holds they “bank “ on you changing your feelings, this is not about feelings, watch this one , it’s real . 🦍
0 · Reply
gargoyl
gargoyl Jan. 16 at 3:26 PM
$BLRX MM counters a 10k Bid with a 20k Ask , spread book wide open , watch as he reconciles the offset , brings her back over $3 .. the forced illusion of weakness accentuates the move up on balance .. Manipulation is temporary, treating cancer is indelible
0 · Reply
gargoyl
gargoyl Jan. 16 at 2:29 PM
$BLRX look 🏃‍♀️
0 · Reply
mfish11
mfish11 Jan. 15 at 8:34 PM
$BLRX this gonna make me rich one day
1 · Reply
gargoyl
gargoyl Jan. 15 at 2:24 PM
$BLRX 👀 - spoofing at 3.10 - past month channel consolidation between 2.80 and 3.10 - RSI primed break 60 - $XBI run 🏃‍♂️ - nearing next ER - MM playing the pull back game widening her book - my book All point to we break $3.00 today 💪 strong Target 🎯 $12 -$18 $REGN long the 🦋
0 · Reply
gargoyl
gargoyl Jan. 14 at 2:45 PM
$VSTM $BLRX 🔮 One will be down 10% Other up 10% today
0 · Reply
silentmaxx
silentmaxx Jan. 13 at 4:13 PM
$BLRX
0 · Reply
gargoyl
gargoyl Jan. 13 at 4:56 AM
$BLRX 3 of 3 Small float , joke of a market cap , target 🎯 $12 to $18 $XBI
0 · Reply
gargoyl
gargoyl Jan. 13 at 4:55 AM
$BLRX 2 of 3 GenFleet & BiolineRx trials .. continue
0 · Reply
gargoyl
gargoyl Jan. 13 at 4:54 AM
$BLRX 👀 reminder 1 of 3 PDAC TAM $XBI
0 · Reply
gargoyl
gargoyl Jan. 12 at 5:31 PM
$VSTM 6.75 is a given , it’s the next leg down that’s in question… knife 🔪 is falling.. $BLRX temp low volume manipulation, wants 3.50
0 · Reply
gargoyl
gargoyl Jan. 9 at 4:53 PM
$BLRX 👀. 🐈‍⬛ alysts … - Partner milestone licensing Rev. - Gloria Biosciences - Partner milestone licensing Rev. - Ayrmid Ltd, / Gamida Cell -Jntv-Vent w/ Hemispherian - GenFleet wildcard - Regeneron wildcard Collaborations: - Columbia U - Washington U - St Jude Indications/ method of activations / treatments: - Gliblastona / Glix1 - motixafortide/ Aphreses ( stem cell mobilization) - PDAC / Solid Tumors / other cancers - SCD - MM - Cash on hand / runaway 2027 / low float / did I say low float / and low float Long the butterfly 🦋 $REGN $VSTM $XBI
0 · Reply
StonkyTonkJoe
StonkyTonkJoe Jan. 8 at 3:29 PM
$BLRX anyone know why I can’t buy more shares on Schwab without calling a broker? I had no problem in the past and then about a month ago I got the notice when I put the order in.
3 · Reply
gargoyl
gargoyl Jan. 8 at 3:05 PM
$VSTM looks like drooping after yesterdays fake pump , will retest lows below $7 $BLRX low float play , value play , growth play , under valued market cap 🧢 play , revenue milestone play .. do dd pull up BiolineRx pipeline, partnerships, collaborations in multiple cancer indications
2 · Reply
gargoyl
gargoyl Jan. 8 at 2:55 PM
$BLRX she’s ready .. watch 🏃‍♀️ 🦍 $REGN $VSTM $XBI
0 · Reply
gargoyl
gargoyl Jan. 5 at 4:17 PM
$BLRX will continue go up $VSTM will continue go down
1 · Reply
gargoyl
gargoyl Jan. 2 at 2:42 PM
$BLRX being manipulated on low volume, will crush up very soon .. $VSTM heading down , off a cliff
1 · Reply
jfrank9
jfrank9 Jan. 1 at 5:36 AM
$BLRX lol 1200% up
3 · Reply
sweddle
sweddle Dec. 30 at 4:51 PM
$BLRX $VSTM
0 · Reply